Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.

“Participating in the program provides grad students with training and an opportunity to share their research, practice their ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Spatial biology first entered the omics scene about a decade ago. Since then, the technology has generated significant buzz ...

Shares in large US and European drugmakers slide, underperforming amid a broad market slump, after President Donald Trump said the US was planning to announce "a major tariff on pharmaceuticals" soon.

Regal Partners saw funds under management (FUM) slide 8.3% in the March quarter, as weaker market conditions drove a negative ...

Discover insights into Anavex's ATTENTION-AD OLE trial results for early Alzheimer's, presented at AD/PD 2025. Click here to ...

Downtown-based biotech firm Onconetix (Nasdaq: ONCO), in an April 3 filing with the Securities and Exchange Commission, ...

President Donald Trump’s exemption of pharmaceuticals from “reciprocal” tariffs limited the declines of biopharma stocks as financial markets tanked late last week—but the specter of future ...

Sapirstein had only held the title for 32 days, assuming the executive chairman role after the company’s latest CEO resigned ...

Spatial transcriptomics technologies opened the door for new kinds of biological measurements, allowing scientists to ...